# Evaluation of a steroid delivery system to mitigate the severity of proliferative vitreoretinopathy in a minipig model

**Authors:** Chee Wai Wong, Ning Cheung, James S. Howden, Joanna Marie Fianza Busoy, Shaun Sim, Joshua Lim, Candice Ho, Amutha Barathi Veluchamy, Gert Storm, Tina T. Wong

PMC · DOI: 10.3389/fopht.2023.1222689 · Frontiers in Ophthalmology · 2023-11-17

## TL;DR

A new steroid delivery system was tested in minipigs to reduce the severity of a retinal disease called proliferative vitreoretinopathy.

## Contribution

Liposomal prednisolone phosphate is shown to reduce PVR severity in a minipig model compared to controls.

## Key findings

- Liposomal prednisolone phosphate significantly reduced severe PVR compared to controls.
- Triamcinolone acetonide showed similar efficacy to liposomal prednisolone phosphate.
- Most eyes treated with liposomal prednisolone phosphate had mild or no PVR.

## Abstract

To investigate the efficacy of liposomal prednisolone phosphate to mitigate the severity of proliferative vitreoretinopathy (PVR) in a minipig model of PVR.

A total of 18 eyes of 9 minipigs underwent PVR induction surgically. Eyes were randomized equally into three groups: intravitreal injection of liposomal prednisolone phosphate (LPP), triamcinolone acetonide (TA), and controls. PVR severity was graded on fundoscopic examination using a modified version of the Silicon Study Classification System. Severe PVR was defined as grade 2-5 on this classification, and the proportion of eyes with retinal detachment from severe PVR, defined as retinal re-detachment, i.e., PVR grade 2-5, was compared between treatment and control groups.

On day 28, five eyes (83.3%) in the control group were observed to have severe PVR. Within the LPP group, one (16.7%) eye developed retinal detachment due to severe PVR. Grade 0 PVR was observed in four (66.7%) eyes, grade 1 in one (16.7%) eye, and grade 5 in one (16.7%) eye. Within the TA group, grade 0 PVR was observed in four eyes (66.7%), grade 1 in two eyes (16.6%), and grade 5 in one (16.7%) eye. The difference in the proportion of eyes with severe PVR was significantly lower in the LPP group compared to controls at day 28 (16.7% vs 83.3%, p=0.02). There was no significant difference in the rate of severe PVR or median PVR grade between the liposomal prednisolone phosphate and triamcinolone acetonide groups.

Liposomal prednisolone phosphate reduces the severity of PVR in a minipig model of PVR.

## Linked entities

- **Chemicals:** prednisolone phosphate (PubChem CID 72078), triamcinolone acetonide (PubChem CID 6436)
- **Diseases:** proliferative vitreoretinopathy (MONDO:0100450)

## Full-text entities

- **Diseases:** retinal detachment (MESH:D012163), PVR (MESH:D018630)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11182131/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11182131/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11182131/full.md

---
Source: https://tomesphere.com/paper/PMC11182131